represent different willingness-to-pay (WTP) thresholds, discount rates, medical costs, and healthcare systems. Apixaban was compared with warfarin/acenocoumarol in 7 of them (27%), with warfarin/NOACs in 14 (54%), with aspirin in 2 (8%), and with warfarin/aspirin in 3 (11%). Models were conducted from Europe (69%), USA (23%), Australia (4%), and Latin America (4%). All models reported cost/ quality-adjusted life years (QALYs) gained, 92% reported using a payer perspective, and 8% using a societal perspective; the median quality score of the selected studies was 89 (out of 119), with a range of 55-103. In models performed in Europe, incremental cost-effectiveness ratios (ICERs) of apixaban versus warfarin ranged from €5607/QALY to €57,245/QALY, while ICERs versus aspirin ranged from being dominant to €7334/QALY. In models carried out in the USA, ICERs of apixaban versus warfarin ranged from being dominant to $93,063/QALY.
Conclusion:
Different cost-effectiveness analyses suggest that apixaban is a cost-effective therapeutic option according to
INTRODUCTION
Apixaban is a new oral anticoagulant (NOAC). It is a direct factor Xa inhibitor with rapid absorption and a 12-h half-life. A total of 25% is eliminated through renal excretion. Apixaban demonstrated its superior efficacy and safety versus warfarin (gold standard) in preventing stroke in patients with non-valvular atrial fibrillation (NVAF) in the ARISTOTLE study [1] and versus aspirin in the AVERROES study [2] (ClinicalTrials.gov identifiers: NCT00412984 and NCT00496769, respectively). Apixaban belongs to the new generation of anticoagulants with fixed-dose oral administration not requiring laboratory controls and having a little interaction with other drugs and foods [3] .
Traditionally, healthcare companies were required to provide evidence to demonstrate product safety, efficacy, and quality for registration and reimbursement purposes.
Increasingly, demonstrating value-for-money, which requires companies to conduct economic evaluations to support the reimbursement process, has been added, increasing the importance of health economic evaluations. Some clinical guidelines [4] take cost-effectiveness data into consideration when positioning therapies for stroke prevention in NVAF. Therefore, an important step in determining the place of NOACs in clinical practice is to evaluate their cost-effectiveness in terms of their effect on healthcare decision-making and hence on health outcomes.
In addition, economic evaluations are becoming increasingly important due to limitations in economic resources, the expense of many new treatments, the need to allocate health spending as effectively as possible, and the need to inform decision makers.
Based on the data from the apixaban studies (ARISTOTLE [1] and AVERROES [2] ), several economic evaluations have been performed in various countries to demonstrate the efficiency of apixaban versus warfarin and aspirin or other NOACs for preventing stroke in patients with NVAF.
The aim of this study was to perform a systematic literature review of published economic evaluations with apixaban indicated for stroke prevention in patients with NVAF.
METHODS

Search Strategy
Once the search topic was established: ''Economic evaluation of apixaban in the indication of stroke prevention in patients with NVAF in Spain and in other countries'', we conducted a systematic literature search in PubMed, Cochrane Library, Google Scholar, and Index Medicus Español (IME) in June 2015 based on the following strategy: ''(apixaban) AND (cost-effectiveness OR efficiency OR economic evaluation) AND (non-valvular atrial fibrillation)''. The literature search was not restricted by publication year.
Inclusion and Exclusion Criteria
The following inclusion criteria were considered (all must have been met):
• Economic evaluations of apixaban performed in any country;
• Economic evaluations of apixaban in the indication of stroke prevention in patients with NVAF;
• Any type of economic evaluation of apixaban (cost minimization analysis, cost-effectiveness analysis, cost-utility (CU)
analysis, and cost-benefit analysis);
• Economic evaluations of apixaban or apixaban and other NOACs versus the gold standard (aspirin or warfarin or coumarin derivative) and other NOACs;
• Original articles.
The following exclusion criteria were considered (none must have been met):
• • Article language other than Spanish, English, French, Portuguese, or Italian;
• Review articles, letters, commentaries, editorials, and papers that only report a study methodology without a result.
Data Extraction
The extraction process consisted of three steps once studies were identified after the search.
First, some studies were excluded just by reading the title, mostly in the case of repeated records. Then, the inclusion and exclusion criteria were applied to limit the records to those that met the criteria. In a second review, the same criteria were applied after reading the selected abstracts to identify relevant studies. Finally, we proceeded to read the full articles of the selected records.
For all relevant articles after review, the main The search was summarized in a CONSORT-style flowchart (PRISMA) [5] .
Quality Assessment
In addition, a weighted version of Drummond's checklist [6] was used to further assess the quality of the selected studies [7] . The checklist is used specifically to assess economic evaluation studies, and it was divided into three main sections: study design, data collection, and the analysis and interpretation of results.
The list consists of 35 items. The weighted version was used in the previous studies [8, 9] and assigns a maximum overall score of 119 (maximum scores of 26 for study design, 48 for analysis and interpretation of results, and 45 for data collection).
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Included Studies
With the aforementioned search strategy:
''(apixaban) AND (cost-effectiveness OR efficiency OR economic evaluation) AND (non-valvular atrial fibrillation)'', 129 articles were found (53 articles from PubMed, 10 articles from Cochrane Library, 43 articles from Google Scholar, and 23 articles from the IME).
In the first review, after reading the titles of all the articles found, nine repeated articles were excluded from the four databases. After applying the inclusion and exclusion criteria, 80 more articles were excluded for the following reasons:
• 6 articles were economic evaluations of other NOACs;
• 10 articles were economic evaluations of apixaban for indications other than stroke prevention in patients with NVAF;
• 61 articles were not appropriate (studies on effectiveness or efficacy, on costs, in languages others than those listed in the exclusion criteria, on pharmacotherapeutic guidelines, etc.);
• 3 articles were review articles.
In the second review, after reading the abstracts of the 40 articles selected after the first review, 14 were discarded for not meeting the inclusion criteria:
• 7 were review articles;
• 4 were not economic evaluations; they were cost studies;
• 2 did not include apixaban among those NOACs tested;
• 1 referred to another article already listed. Finally, 26 articles were selected for full reading. After reading the articles, none of them were excluded ( Fig. 1 ). Table 1 shows the quality assessment results of the studies using the weighted version of Drummond's checklist [7] . All of the studies clearly defined the research question (item 1), The time horizon of costs and benefits was stated (item 22), as was the discount rate (item 23). The approach to sensitivity analysis was given (item 27). All the studies compared hemorrhages, other major hemorrhages, and minor bleeding).
Drummond's Checklist
All published evaluations except seven used the perspective of the payer, including only direct costs. Four studies [20, 29, 32, 34] presented the results from a societal perspective, and three studies [13] [14] [15] presented both societal and payer perspectives.
All publications except four used a lifetime horizon for the included subjects: two of them Five studies compared apixaban with the standard therapy of warfarin or acenocoumarol [10, 14, 28, 33, 34] . Two studies compared apixaban with aspirin [18, 35] . Three studies compared apixaban with warfarin and aspirin [20, 23, 27] . One study compared apixaban with warfarin, aspirin, rivaroxaban, and dabigatran [21] . One study compared apixaban with rivaroxaban and dabigatran [24] . One study compared apixaban, rivaroxaban, and dabigatran with coumarin derivatives [17] .
One study compared apixaban with vitamin K antagonists (VKAs) [19] . Eight studies compared warfarin with apixaban, dabigatran, and rivaroxaban [12, 16, 22, 25, [29] [30] [31] [32] . One study compared apixaban with dabigatran [15] , and one study compared apixaban with rivaroxaban [13] . Finally, two models compared the efficiency of warfarin with genotype-guided warfarin, apixaban, dabigatran, and rivaroxaban, and one of them also included edoxaban [11, 26] . All articles included both (cost/life year gained) [13-17, 19, 27, 28] .
All the selected articles based their results on the appropriate decision rates (incremental CU and cost-effectiveness ratios). When compared to adjusted-dose VKA (warfarin and acenocoumarol in the great majority of the articles), apixaban was invariably associated with a better clinical and safety profile. In addition, apixaban was cost-effective compared to warfarin and aspirin and the rest of the pharmacological strategies compared in most of the included economic evaluations according to the cost-effectiveness thresholds used in various countries ( Table 2) .
The mean incremental QALY of apixaban versus warfarin was of 0.219, with a range of 0.137-0.5, being dominant option in a study [33] . When comparing apixaban with aspirin, the mean incremental QALY was of 0.28 with a range of 0.27-0.29, being a dominant option in a study [35] . In general, all the studies indicated that apixaban was cost effective with ICERs below the willingness-to-pay (WTP) threshold, if not dominant (Table 2 ). In evaluations performed in Europe, the mean ICER was of €16,502/ QALY, with a range from €7212/QALY to €57,245/QALY, while ICERs versus aspirin ranged from being dominant to €7334/QALY. In models performed in the US, ICERs of apixaban versus warfarin ranged from being dominant to $93,063/QALY; in addition, apixaban was a dominant option versus aspirin in a study performed in the US [35] .
In the deterministic sensitivity analysis, the results of these models were typically sensitive to changes in the cost of apixaban, Apixaban, an oral direct factor Xa inhibitor, is the third NOAC to receive marketing authorization from the European Union for the prevention of stroke and systemic embolism in NVAF. It is the only NOAC that has been shown to be superior to dose-adjusted warfarin in terms of reducing stroke, systemic embolism, major bleeding, and all-cause mortality rates [40] . Since apixaban results in better health outcomes than VKAs (especially less major bleeding and a significant reduction in the stroke rate), it is crucial for health professionals and drug policy decision makers to know whether or not the routine use of apixaban in patients with NVAF is a cost-effective therapeutic option. performed following the highest quality standard methodology to build analytical decision models and with scientific rigor, so the results will be valid and accurate; in fact, the quality of the economic evaluations was assessed as high, yet some quality items were not met. Moreover, most of economic evaluations applied a probabilistic sensitivity analysis, following the recommendations of some country guidelines to elaborate this kind of analysis and some health technology assessment agencies along with a cost-effectiveness acceptability curve, so it was possible to estimate probabilities of cost effectiveness at different WTP thresholds.
However, it was not possible to fully compare the economic evaluations, as the results were calculated on the basis of varying alternative treatment approaches, and thereby they were not fully homogeneous. It might be more accurate to compare apixaban treatment to the actual prescribing pattern of warfarin in clinical practice, as the treatment quality in a trial setting might be higher than in clinical practice due to a higher degree of monitoring. 
